Molecular Imaging in Drug Discovery and Development
This whitepaper discusses the role of molecular imaging in the drug discovery and development process.
Key takeaways
- Preclinical imaging can support different phases of drug discovery and development, hereby reducing biological variability and cost.
- Preclinical imaging is a non-invasive and longitudinal research tool, it is fully compliant with the 3Rs principles which allows the researchers to study interactions of new compounds in real time in a quantitative manner at a molecular level. Additionally, it provides the ability to repeatedly and non-invasively monitor treatment response. Importantly, preclinical imaging can also increase your research throughput significantly.
- There are many well-established techniques in drug discovery and development that can be complemented with preclinical molecular imaging, providing similar or additional info in a non-invasive and quantitative manner (e.g. target expression levels, biodistribution, etc.)
- CUBES offers the drug discovery community a benchtop imaging platform to produce reproducible, quantitative and biologically relevant data that enables an acceleration in the drug discovery process
Download this Document:
Please enter your details below to gain on-demand access to this Document.